Ribose cysteine (RibCys) is a cysteine prodrug that increases both hepatic and renal glutathione with documented antagonism of acetaminophen (APAP)-induced hepatotoxicity. To determine if RibCys could also protect against APAP-induced kidney damage, mice were injected with APAP (600 mg/kg) or APAP and RibCys (1.0 g/kg) (APAP/RIB) followed by additional RibCys injections 1 and 2 hours later. Mice were euthanatized 10-12 hours after APAP administration, and liver and kidney toxicity were assessed by plasma sorbitol dehydrogenase (SDH) activity and blood urea nitrogen (BUN), respectively, and by histopathology. APAP treatment resulted in elevation of SDH activity and BUN to 2,490 U/ml and 47 mg/dl, respectively. By contrast, SDH and BUN values for APAP/RIB-treated mice were not different from controls, 0 U/ml and 31 mg/dl, respectively. Histopathologic examination revealed moderate to severe hepatic centrilobular necrosis in 9/11 and renal proximal tubular necrosis in 10/11 APAP-treated mice. However, no evidence of hepatic or renal toxicity was noted in any of the 12 APAP/RIB-treated mice. Utilizing the same treatment regimen, APAP covalent binding to hepatic and renal cytosolic proteins was assessed 4 hours after APAP challenge. RibCys cotreatment decreased covalent binding to the 58-kDa acetaminophen-binding protein in both liver and kidney. RibCys decreased both toxicity and covalent binding after APAP administration, and in addition to protecting the liver, this cysteine prodrug can also effectively protect the kidney from APAP-induced injury.
INTRODUCTION
Acetaminophen (APAP, 4-hydroxyacetanilide, paracetamol) is a widely used analgesic and antipyretic agent found in many over-the-counter and prescription drugs. Although APAP is relatively safe at therapeutic doses, overdose can cause severe centrilobular necrosis and renal proximal tubular necrosis in humans and laboratory animals (6, 7, 17, 30, 42) . In humans, peak disturbances in liver function develop 2-4 days after overdose, with renal disturbances developing anywhere from 2 to 14 days after poisoning (7, 39) . In the United States and Europe, there were 119,861 incidences of APAP overexposure reported to poison control centers in 1997; approximately 2% of the cases resulted in major complications, and 0.1°7o resulted in death (35) . Although the major concern with APAP overdose is hepatotoxicity, it is estimated that renal damage occurs in 1/1,000 poisonings (11, 24) . In addition, there are reports of APAPinduced renal necrosis in humans in the absence of fulminant hepatic necrosis or portosystemic encephalopathy (4, 5, 11, 21, 55) . N-acetylcysteine (NAC, Mucomyst), administered orally or intravenously, is the preferred antidote for APAP poisoning (20, 34) . Although there is ample evidence to indicate that NAC treatment can prevent or reverse APAP-induced hepatocellular damage in humans if administered within 12 hours after overdose (9, 37) , its therapeutic application is not without adverse effects. Complications associated with oral administration include nausea and vomiting, resulting in incomplete delivery of the intended dose (51) . Several incidences of anaphylactic reactions, including bronchospasm, angioedema, and hypotension (54) , have also been associated with intravenous administration (23) . For some clinical cases, administration of NAC reversed liver damage but not kidney damage (16, 31 ) .
In previous studies (2, 3, 19, 25, 27, 45) , the CD-1 mouse has been used as a model for APAP-induced he-patic and renal toxicity. With APAP overdose, a larger percentage of the dose is metabolized by cytochrome P-450 to a reactive electrophile, N-acetyl-p-benzoquinoneimine (NAPQI) following saturation of the primary detoxification pathways (10, 18, 42) . Detoxification of NA-PQI by formation of glutathione (GSH) conjugates is accompanied by decreased levels of intracellular GSH and by covalent binding of NAPQI to cellular proteins (29, 43) . Subsequently, a number of studies have established a correlation between the extent of covalent binding to a 58-kDa cytosolic protein (58-ABP) and toxicity in mice, and similar 58-ABP binding has been identified in human liver after APAP overdose (2, 3) . As with humans, oral administration of NAC also protected against APAP-induced liver, but not kidney damage, in the mouse (26) . Moreover, NAC prevented APAP-induced GSH depletion and protein arylation in the liver but not the kidney, which suggests that orally administered NAC may not adequately deliver cysteine to the kidney or that other tissue specific differences, eg, in transport or conjugation reactions, play a role. Collectively, the results of both clinical and experimental studies indicate that because NAC may not always be effective in preventing or reversing APAP-induced nephrotoxicity, it is important to assess other compounds for their potential efficacy against APAP-induced renal injury. Ribose cysteine [2(R,S)-D-ribo-(1',2',3',4'-tetrahydroxybutyl)thiazolidine-4(R)-carboxylic acid; RibCys] ( Figure 1 ), a cysteine prodrug, has been shown to increase hepatic and renal GSH content in nonfasted CDFI I mice (47) . RibCys also protected against APAP-induced hepatotoxicity in male Swiss-Webster mice (46) ; however, its effectiveness in reducing renal damage has not been examined nor has its effect on covalent binding in either tissue been determined. The present study was conducted to determine whether RibCys can also protect against APAP-induced renal toxicity in the well-characterized CD-1 mouse model of APAP toxicity (44) . The findings document such protection and suggest that RibCys may represent a suitable alternative or adjunct antidote for NAC.
MATERIALS AND METHODS
Materials. Acetaminophen, propylene glycol, fructose, sodium chloride, triethanolamine, ¡3-NAD (disodium salt, reduced form), blood urea nitrogen (BUN) diagnostic kit 66-20, acrylamide, glycine, trizma-base, sodium dodecyl sulfate, Tween-20, fish gelatin, and goat anti-rabbit IgG labeled with horseradish peroxidase were purchased from Sigma Chemical Co (St Louis, MO). Bis-acrylamide was purchased from Boehringer Mannheim Chemicals (Indianapolis, IN). The chemicals listed above and all other chemicals used were reagent grade or better. RibCys was synthesized as previously described (48) .
Animals and Treatments. The 3-5-month-old male Crl:Cd-1(ICR)BR mice were purchased from Charles River Laboratories (Wilmington, MA) and housed in a temperature-and humidity-controlled facility in cages with steel-wire bottoms over hardwood chips (Sani-Chips, PJ Murphey Forest Products, Montville, NJ). The mice were fed Purina Rodent Chow (#5001, Ralston Purina Co, St Louis, MO) ad libitum and were allowed to acclimate to this environment with a 12-hour light-dark cycle for at least 2 weeks after arrival. Mice were kept from food for 18 hours prior to drug treatment, and drugs were administered between 9 and 11 am. The fasted male CD-1 mouse model response to APAP has been thoroughly characterized (44) , and fasted mice exhibit a more consistent response to APAP than do fed mice. To determine whether RibCys could protect against APAP-induced liver and kidney toxicity, mice were challenged with a single dose of APAP (600 mg/kg intraperitoneally [IP] ) in a 50:50 propylene glycol/water mixture (PG; 5 ml/kg). RibCys (1.0 g/kg IP) in 10 mM phosphate-buffered saline (PBS, pH 7.4) was administered simultaneously with the APAP treatment (APAP/RIB) and again at 1 and 2 hours after APAP Appropriate controls included animals that received (a) APAP with PBS instead of RibCys (APAP/PBS), (b) PG in the place of APAP with RibCys (PG/RIB), and (c) PG and PBS (PG/PBS) as vehicle controls. The mice were euthanatized by decapitation 10-12 hours after APAP treatment, and trunk blood was collected in heparinized microtubes and separated at 5,000 rpm for 5 minutes in a Brinkmann Eppendorf 5414 microcentrifuge. The resulting plasma was analyzed for sorbitol dehydrogenase (SDH) activity and BUN. Sections of livers and kidneys were collected and stored in 10% buffered formalin for histopathologic preparation and analysis. To determine whether RibCys cotreatment altered APAP covalent binding to cytosolic proteins in the liver and the kidney, additional animals were treated as described above but were euthanatized 4 hours after APAP administration, and liver and kidney tissue was placed in ice cold STM buffer (0.250 M sucrose, 10 mM Trizma base, 1 mM MgC'2-6H20, pH 7.4).
Assessment of Liver and Kidney Toxicity. Plasma SDH activity, an indicator of hepatocellular damage, was measured according to the method of Gerlach and Hiby (22) as modified for a 96-well microtiter plate reader (38) . BUN was measured as an index of renal function and tubular damage.
Histopathologic Methods and Analysis. Formalinfixed sections were embedded in paraffin, sectioned to 5 J.1m, and stained with hematoxylin and eosin. The sections were examined by light microscopy for the presence of hepatic centrilobular and renal tubular necrosis, which was graded on a scale of 0 to +5 as described by Emeigh Hart et al. (19) : 0 = no lesions; + 1 = minimal lesions (single to few necrotic cells or tubules); +2 = mild le- Plasma was collected 10-12 hours after APAP treatment and was analyzed for SDH activity. Letters different from each other represent a significant difference (p ~ 0.05). sions (10-25% necrotic cells or tubules or mild diffuse tubules and degenerative changes); +3 = moderate lesions (25-40% necrotic or degenerate cells or tubules); +4 = marked lesion (40-50% necrotic or degenerate cells or tubules); +5 = severe lesions (>50% necrotic cells or tubules). Scores ~2 were considered evidence of toxicant induced injury.
Determination of APAP Covalent Binding in Cytosol.
Liver and kidney tissues were homogenized (10% w/v) in ice cold STM buffer. Homogenates were centrifuged at 4°C for 20 minutes at 9,000 X g in a Beckman J2-21
centrifuge. The resulting supernatant was then centrifuged at 4°C for 1 hour at 100,000 X g in a Beckman L7 ultracentrifuge for the collection of the cytosolic fraction. Protein concentration of the liver and kidney cytosols was determined by the method of Lowry et al. (36) . Cytosolic proteins (30 a.b.c Letters different from each other represent significant differences between groups (p :5 0.05).
d One additional animal was omitted from the histologic and statistical analysis because histologic examination indicated that injury was consistent with accidental penetration of the liver parenchyma during the IP injection. It was not included in the % ~+2 calculations. jected to 3 additional 5-minute washes. Covalently bound proteins were detected using ECL western blotting reagents (Ammersham Life Sciences, Arlington Heights, IL), and blots were exposed to Fuji medical x-ray film (Fisher Scientific, Springfield, NJ). Quantitation of APAP covalent binding was performed using a PDI densitometer with PDI Quantity One software (Biorad, Rockford,
IL)
Statistics. SDH, BUN, and histopathology data were analyzed using a 2-way analysis of variance followed by a Newman-Keuls post hoc test to determine if there were statistical differences between treatment groups (Statistica computer software, Statsoft, Tulsa, OK). Histopathology scores were converted to ranks prior to analysis. Covalent binding data were analyzed using Student's t-test.
Differences between treatment groups were considered significant at p ~ 0.05.
RESULTS
RibCys Prevention of APAP-Induced Hepatotoxicity Mice exposed to APAP exhibited a significant elevation in plasma SDH activity (2,487 ± 1,014 U/ml) 12 hours after APAP challenge (Figure 2 ). By contrast, SDH activity was not detected in plasma obtained from PGtreated control mice or, more importantly, in plasma from mice that received the RibCys cotreatment (Figure 2 ). Similar RibCys protection against APAP toxicity was also observed at 24 hours after APAP in RibCys cotreated mice (data not shown). In addition, RibCys protection against APAP-induced elevation of plasma SDH was also confirmed by histopathologic analysis. APAP treatment in the absence of RibCys cotreatment caused moderate to severe centrilobular hepatic necrosis in 10/11 1 animals (Table 1 ). APAP treatment resulted in hepatocellular necrosis and congestion of the sinusoids in the centrilobular region, whereas cells in the periportal region were normal (Figure 3a ). In agreement with RibCys prevention of elevated plasma SDH activity, liver necrosis was not observed in any of the 12 APAP-challenged mice that received RibCys cotreatment (Table 1 and Figure 3b ). Scores were below 2, indicating no biologically significant injury, for livers of animals that received RibCys treatment in the absence of APAP or in vehicle controls (Table 1 ). These observations of RibCys protection against APAP-induced hepatotoxicity in CD-1 mice are consistent with an earlier report of similar protection in Swiss-Webster mice (46) . (Figure 4 ). Plasma BUN was elevated 2.6-fold above that of vehicle-treated controls (47.19 mg/dl) 10-12 hours after APAP challenge. Cotreatment with RibCys lowered plasma BUN to 31.41 mg/dl, which was not significantly different from that of vehicle or RibCys controls (Figure 4 ). Similar RibCys protection against APAP-induced nephrotoxicity was observed 24 hours after APAP treatment (data not shown). (Table 2) confirmed the results of the BUN assay. Treatment with APAP produced mild to moderate renal proximal tubular necrosis in 10/11 1 mice, whereas all of the 13 animals cotreated with RibCys had histopathology scores of 0. Coagulative necrosis was evident in multiple proximal tubules in mice treated with 600 mg APAP/kg (Figure 3c ). Examination of other microscope fields revealed changes in cytoplasmic staining, nuclear pyknosis, karyorrhexis, etc (data not shown). However, no such changes were evident in the kidneys of mice given the RibCys cotreatment ( Figure  3d ). No lesions were detected in kidney sections from animals treated with RibCys alone or with vehicle (Table  2) . Thus, as with hepatotoxicity, APAP-induced renal toxicity was also prevented by RibCys cotreatment.
RibCys Prevention of APAP-Induced Nephrotoxicity

Histopathologic analysis
E, ffeet of RibCys on APAP Covalent Binding to Liver and Kidney Cytosolic Proteins
The rates of NAPQI formation and elimination are important determinants of the extent of covalent binding and subsequent cell damage. Moreover, a number of studies -. have shown that there is a close inverse correlation between the levels of intracellular GSH and covalent binding or toxicity (15, 43) . Because RibCys stimulates GSH synthesis in vitro and in vivo (47) , the protection observed following RibCys administration may be attributed to an increased amount of APAP-GSH and a decrease in the net availability of NAPQI. To determine whether RibCys protection against APAP toxicity is associated with diminished availability of the electrophile, covalent binding to hepatic and renal cytosolic proteins was determined 4 hours after APAP challenge by western blot analysis with anti-APAP antibodies (1) . In agreement with previous work (19, 38) , specific APAP binding to the 58-and 44-kDa proteins in hepatic cytosol and the 58-and 33-kDa proteins in renal cytosol was observed in unprotected mice (Figures 5 and 6 ). Quantitative image analysis of the blots in Figure 5a revealed that RibCys cotreatment did not alter the total amount of covalent binding to liver cytosolic proteins 4 hours after APAP challenge (Figure 5b ). However, selective APAP covalent binding to 58-kDa acetaminophen-binding protein (58-FIGURE 5.-Effect of RibCys (APAP/RIB) cotreatment on APAP covalent binding to liver cytosolic proteins. Mice were given a single dose of APAP (600 mg/kg IP) that was immediately followed by RibCys (1.0 g/kg IP). Additional RibCys treatments were repeated 1 and 2 hours after APAP challenge. Alternatively, mice were given APAP and PBS (APAP/PBS), PG and RibCys (PG/RIB), or PG and PBS (PG/PBS). A) Liver cytosol was obtained from mice euthanatized 4 hours after APAP treatment and was analyzed for APAP covalent binding. Cytosols from mice treated with APAP (n = 3) and APAP/RIB (n = 7) are representative for each treatment group. The most prominent hepatic cytosolic adducts were the 58-ABP and 44-ABP. No binding was detected in control cytosol (lane C). B) Densitometric analysis revealed that RibCys cotreatment did not significantly decrease total APAP binding but decreased APAP covalent binding to 58-ABP Letters different from each other represent a significant difference @ S 0.05). wyiosol oo-/-xt5t-OO-/£t5U FIGURE 6.-Effect of RibCys (APAP/RIB) cotreatment on APAP covalent binding to kidney cytosolic proteins. Mice were given a single dose of APAP (600 mg/kg IP) that was immediately followed by RibCys (1.0 g/kg IP). Additional RibCys treatments were repeated 1 and 2 hours after APAP challenge. Alternatively, mice were given APAP and PBS (APAP/PBS), PG and RibCys (PG/RIB), or PG and PBS (PG/PBS). A) Renal cytosol was obtained from mice euthanatized 4 hours after APAP treatment and was analyzed for APAP covalent binding. Cytosols from mice treated with APAP (n = 3) and APAP/RIB (n = 7) are representative for each treatment group. The most prominent renal cytosolic adducts were the 58-ABP and 33-ABP No binding was detected in control cytosol (lane C). B) Densitometric analysis revealed that RibCys cotreatment decreased APAP covalent binding to cytosolic proteins and to these target proteins. Letters different from each other represent a significant difference (p :5 0.05). ABP) in the liver was significantly decreased in APAPtreated mice given RibCys (Figure 5b ). By comparison, in the kidney, there was a significant decrease in not only the total amount of covalent binding to cytosolic proteins (Figure 6a , b) but also in specific binding to 58-ABP and (Figure 6b ).
DISCUSSION
The results of this study support the previous finding that RibCys protects against APAP-induced hepatotoxicity (46) , but they also demonstrate that RibCys treatment also protects against APAP-induced nephrotoxicity in male CD-1 mice, a model in which NAC is ineffective (26) . Although APAP exposure alone resulted in mild to severe centrilobular necrosis and renal proximal tubular necrosis in 91 % of the animals, RibCys was effective in preventing this toxicity, with no necrotic lesions detected in animals that received the RibCys cotreatment.
RibCys protection against APAP toxicity may lie in its ability to trap or decrease the net amount of available NAPQI that can covalently bind to cellular proteins. APAP covalent binding is thought to be important for the initiation of toxicity (12) (13) (14) , and covalent binding to specific cellular proteins is correlated with hepatic and renal toxicity (2, 19) . The preferential target for APAP in liver and kidney cytosol is a 58-ABP that is homologous to a selenium-binding protein (28, 33) . RibCys did not decrease the overall amount of covalent binding to cytosolic proteins in the liver, but it did decrease APAP binding to hepatic 58-ABP ( Figure 5 ). This effect suggests that although RibCys did not decrease the overall amount of NAPQI in the liver, it may have affected the availability of NAPQI to interact with specific protein targets. Previously, we have shown that specific covalent binding to 58-ABP better correlates with hepatotoxicity than does total binding to cytosolic proteins (2) . Thus, studies using 2-and 3-month-old mice demonstrated that binding to 58-ABP segregated with an increased sensi-tivity to APAP (600 mg/kg) in the 3-month-old mice, as compared with the more resistant 2-month-old mice. Total cytosolic binding was the same in both age groups, suggesting that APAP binding to 58-ABP was more closely correlated with APAP-induced hepatotoxicity.
In the kidney, RibCys cotreatment decreased both the total amount of binding to cytosolic proteins and the binding to 58-ABP and 33-ABP, another frequent APAP target in mouse kidney ( Figure 6 ). This decrease in both total and specific renal APAP adducts suggests that RibCys treatment does reduce the net availability of NA-PQI in renal proximal tubules. This reduction may be attributed to a direct interaction of RibCys with NAPQI or through the delivery of cysteine, which may trap NA-PQI to form APAP-cysteine conjugates. RibCys may also serve to supply cysteine for GSH synthesis; cysteine is released upon nonenzymatic hydrolysis of the thiazolidine ring (49) . In rat hepatocytes, GSH increased 1.7fold after RibCys treatment, but this increase was prevented by buthionine sulfoximine (49) . In vivo, administration of RibCys to mice increased liver and kidney GSH approximately 1.5-fold above control levels at 16 hours (47) . Thus, elevation of GSH could serve to trap NAPQI or to antagonize the oxidative stress associated with APAP toxicity, or both. Additional studies will be needed to resolve these possible modes of action. Because plasma APAP levels were not measured after RibCys administration, the protection might be explained on the basis of altered APAP pharmacokinetics after the RibCys treatment. However, this alteration is unlikely because preliminary studies have shown that the RibCys protection against APAP toxicity can be blocked by inhibiting GSH biosynthesis (unpublished data). This blockage would not be expected if the protection were simply an issue of altered pharmacokinetics and thus suggests that the mechanism of protection is dependant upon RibCys enhancement of GSH production. Additional factors other than increased GSH biosynthesis, eg, differ-ences in uptake between RibCys and NAC or other as yet unidentified factors, may account for the greater efficacy of RibCys in renal protection against APAP toxicity.
RibCys is nontoxic to CD-1 mice at the doses employed (up to 3 g or 11.86 mmol/kg over 3 hours) and thus may be a candidate for use as an alternative antidote for treatment of APAP poisoning. The apparently large dose of RibCys used in these studies is not very different from the large amount of NAC that is routinely employed for treatment of APAP overdose in humans. NAC antidotal therapy involves an initial loading dose of 140 mg/ kg followed by a maintenance dose of 70 mg/kg every 4 hours for 17 additional doses (total NAC = 1.120 g or 6.87 mmol/kg) (50) . Other cysteine prodrugs that have been clinically evaluated as antidotes for APAP poisoning include methionine and mercaptamine (cysteamine). Similar to NAC, methionine supplies cysteine (40) for GSH biosynthesis, and when administered within [8] [9] [10] hours of APAP ingestion methionine is protective against APAP-induced toxicity (41, 53) . However, Vale et al. (53) reported that a patient given oral methionine within 10 hours of overdose developed transient renal failure in the absence of fulminant liver damage. Cysteine-isopropyl ester hydrochloride elevated liver and kidney nonprotein sulfhydryl content in male BALBc mice and protected them against APAP-induced hepatotoxicity and mortality (8) , but its ability to protect against APAP-induced nephrotoxicity has not been reported.
The novel cysteine prodrug, RibCys, protects CD-1 mice against APAP-induced hepatic and renal toxicity and decreases covalent binding to the 58-ABP in liver and kidney cytosol. These promising results suggest that RibCys should be further examined as an alternative or adjunct antidotal treatment for APAP poisoning.
